Valuation: Aquestive Therapeutics, Inc.

Market Cap 476M 413M 386M 354M 668M 45.32B 680M 4.55B 1.78B 22.6B 1.79B 1.75B 74.55B P/E 2026 *
-9.36x
P/E 2027 * -9.76x
Enterprise Value 391M 339M 317M 291M 548M 37.22B 558M 3.74B 1.46B 18.56B 1.47B 1.43B 61.23B EV / Sales 2026 *
7.73x
EV / Sales 2027 * 6.61x
Free-Float
96.94%
Yield 2026 *
-
Yield 2027 * -
1 day+2.57%
1 week+1.61%
Current month+2.57%
1 month-9.33%
3 months-9.76%
6 months-7.56%
Current year-41.33%
1 week 3.56
Extreme 3.56
3.82
1 month 3.56
Extreme 3.56
4.38
Current year 2.93
Extreme 2.93
6.59
1 year 2.93
Extreme 2.93
7.55
3 years 1.25
Extreme 1.2514
7.55
5 years 0.62
Extreme 0.618
7.55
10 years 0.62
Extreme 0.618
20.7
Manager TitleAgeSince
Chief Executive Officer 50 17/05/2022
Director of Finance/CFO 67 31/12/2020
Compliance Officer - 02/04/2026
Director TitleAgeSince
Chairman 72 01/04/2024
Director/Board Member 60 01/01/2004
Director/Board Member 50 17/05/2022
Date Insider Type Main position Quantity % Market Cap.
16/7/26 Sell

Chief Executive Officer

-20,369 0.0162%
9/3/26 Free

General Counsel

200,311 0.1642%
9/3/26 Other

Chief Operating Officer

168,291 0.1379%
Change 5-day change 1-year change 3-year change Capi.($)
+2.57%+1.61%-0.79%+73.85% 476M
-2.39%-6.36%+47.10%+149.66% 1T
-0.76%-4.34%+52.04%+49.09% 613B
-2.33%-4.60%+25.55%+64.44% 433B
+0.68%-1.14%+38.47%+33.36% 350B
-1.66%-3.13%+32.18%+39.79% 292B
-8.96%-10.77%+3.57%+5.50% 239B
-1.37%-7.41%-2.10%-43.67% 206B
-1.63%+0.69%+27.62%+64.23% 204B
+0.72%+0.48%+15.88%+73.64% 163B
Average -1.13%-3.33%+23.95%+50.99% 350.09B
Weighted average by Cap. -0.93%-4.34%+34.73%+70.96%

Financials

2026 *2027 *
Net sales 50.51M 43.9M 40.99M 37.63M 70.94M 4.81B 72.18M 483M 189M 2.4B 190M 186M 7.92B 71.92M 62.5M 58.35M 53.57M 101M 6.85B 103M 688M 269M 3.42B 270M 264M 11.28B
Net income -50.65M -44.02M -41.1M -37.73M -71.13M -4.83B -72.37M -485M -190M -2.41B -190M -186M -7.94B -47.99M -41.71M -38.94M -35.75M -67.41M -4.57B -68.58M -459M -180M -2.28B -180M -176M -7.52B
Net Debt -85M -73.87M -68.97M -63.31M -119M -8.1B -121M -813M -319M -4.04B -319M -312M -13.33B -
Logo Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Employees
147
Date Price Change Volume
03/08/26 USD 3.790 +2.57% 2,381,422
31/07/26 USD 3.695 -0.67% 1,785,710
30/07/26 USD 3.720 +3.33% 1,446,648
29/07/26 USD 3.600 -4.26% 2,584,958
28/07/26 USD 3.760 +0.80% 2,820,715
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.790USD
Average target price
8.889USD
Spread / Average Target
+134.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AQST Stock